Showing 1 - 7 results of 7 for search 'Ling-Ming Tseng', query time: 0.03s Refine Results
  1. 1
    The development and validation testing of a comprehensive frailty assessment in women with breast cancer

    The development and validation testing of a comprehensive frailty assessment in women with breast cancer by Sheng-Miauh Huang, Ling-Ming Tseng, Chi-Cheng Huang, Pei-Ju Lien, Su-Chen Fang, Yinhui Hong

    Published 2025-02-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Survival outcomes in trial defined high-risk hormone receptor-positive/human epidermal growth factor receptor II-negative early breast cancer: impact of adjuvant chemotherapy

    Survival outcomes in trial defined high-risk hormone receptor-positive/human epidermal growth factor receptor II-negative early breast cancer: impact of adjuvant chemotherapy by Ta-Chung Chao, Deanna Gracia, Chan-Heng Ho, Hao-Yang Chen, Chi-Cheng Huang, Ling-Ming Tseng

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Identifying breast cancer risk factors and evaluating biennial mammography screening efficacy using big data analysis in Taiwan

    Identifying breast cancer risk factors and evaluating biennial mammography screening efficacy using big data analysis in Taiwan by Chi-Cheng Huang, Tzu-Pin Lu, Yu-Jen Wang, Bo-Fang Chen, Hui-Ting Yang, Wei-Pin Chang, Ling-Ming Tseng

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    HDAC inhibitors modulate Hippo pathway signaling in hormone positive breast cancer

    HDAC inhibitors modulate Hippo pathway signaling in hormone positive breast cancer by Ting-I Lin, Yi-Ru Tseng, Min-Jyun Dong, Chih-Yi Lin, Wei-Ting Chung, Chun-Yu Liu, Yi-Fang Tsai, Chi-Cheng Huang, Ling-Ming Tseng, Ta-Chung Chao, Jiun-I Lai

    Published 2025-02-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Abemaciclib combined with endocrine therapy as adjuvant treatment for hormone-receptor-positive, HER2−, high-risk early breast cancer: 5-year Chinese population analysis of the phase III randomized monarchE study

    Abemaciclib combined with endocrine therapy as adjuvant treatment for hormone-receptor-positive, HER2−, high-risk early breast cancer: 5-year Chinese population analysis of the pha... by Qingyuan Zhang, Kunwei Shen, Chuan-gui Song, Quchang Ouyang, Zhenzhen Liu, Qiang Liu, Jifeng Feng, Joanne W. Y. Chiu, Jinhai Tang, Zefei Jiang, Ling-Ming Tseng, Xiaojia Wang, Liu Yang, Chenxi Qian, Zhimin Shao

    Published 2024-10-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study

    Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study by Sung-Bae Kim, Hope S Rugo, Sara A Hurvitz, Hong-Tai Chang, Chiun-Sheng Huang, Su-Hua Lee, Jung-Tung Hung, Shir-Hwa Ueng, Shin-Cheh Chen, Alice L Yu, Ling-Ming Tseng, Louis W C Chow, Ming-Feng Hou, Richard B Schwab, James L Murray, Hsien-Kun Chang, Chwen-Cheng Chen

    Published 2020-10-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort

    Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort by Xichun Hu, Qingyuan Zhang, Tao Sun, Huihua Xiong, Wei Li, Yuee Teng, Yen-Shen Lu, Ling-Ming Tseng, Min Yan, Hongsheng Li, Danmei Pang, Shin-Cheh -Chen, Wenyan Chen, Ou Jiang, Jingfen Wang, Xinhong Wu, Xian Wang, Aimin Zang, Xiaojia Wang, Julie M. Collins, Ethan Fan, Lin Jiang, Xiaoling Zeng, Nicholas C. Turner

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: